Parexel International Corp (PRXL) 46.70 $PRXL
Post Earnings Update: Parexel International Has Climbed 0.9% Higher in Past Week (PRXL)
Comtex SmarTrend(R) - Mon May 12, 11:22AM CDT
When Parexel International (NASDAQ
RXL) reported earnings 13 days ago on April 29th, 2014, analysts, on average, expected the company to report earnings of $0.54 on sales of $493.3 million. Parexel International actually reported earnings of $0.56 per share on sales of $577.9 million, beating EPS estimates by $0.02 and beating revenue estimates by $84.6 million. Shares of Parexel International have climbed from $45.48 to $45.91, representing a gain of 0.9% since the company reported earnings 13 days ago.
PAREXEL Chairman And CEO Named 2014 Immigrant Entrepreneur of the Year in Life Sciences
PR Newswire - Fri May 09, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that its Chairman and CEO, Josef von Rickenbach, was named 2014 Immigrant Entrepreneur of the Year in Life Sciences by the Immigrant Learning Center of Malden, Mass. He received the award May 8, 2014, during the third annual Immigrant Entrepreneur Awards Dinner in Cambridge, Mass.
Healthcare Companies Report Studies, Financial Results, and Upcoming Conferences - Analyst Notes on Vertex, PerkinElmer, PAREXEL, ACADIA Pharmaceuticals and Arena Pharmaceuticals
PR Newswire - Thu May 08, 11:31AM CDT
Today, Analysts Review released its analysts' notes regarding Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2188-100free.
PAREXEL International to Present at Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Tue May 06, 9:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas, NV. James Winschel, Executive Vice President, will be making a presentation on PAREXEL and discussing business developments at 4:20 p.m. PDT on Tuesday, May 13, 2014.
PAREXEL Q3 Earnings & Revs Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 2:00PM CDT
For fiscal 2014, PAREXEL International Corporation (PRXL) increased its adjusted EPS guidance to a range of $2.11 to $2.15 from the prior range of $2.01 to $2.11.
Water-Logged And Getting Wetter Stock Of The Day: Parexel International (PRXL)
at The Street - Wed Apr 30, 9:08AM CDT
Trade-Ideas LLC identified Parexel International (PRXL) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
PAREXEL International Reports Third Quarter Fiscal Year 2014 Results
PR Newswire - Tue Apr 29, 3:06PM CDT
PAREXEL International Corporation (NASDAQ: PRXL) today reported financial results for the third quarter of Fiscal Year 2014, which ended on March 31, 2014.
Technical Coverage on Health Care Equities -- Research on MEDNAX, Covance, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Apr 22, 11:55AM CDT
On Monday, April 21, 2014, the NASDAQ Composite ended at 4,121.55, up 0.64%, the Dow Jones Industrial Average advanced 0.25% to 16,449.25, and the S&P 500 closed at 1,871.89, up 0.38%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 666.48, up 1.20%, while the same has declined 3.26% in the last one month. Investor-Edge has initiated coverage on the following equities: MEDNAX Inc. (NYSE: MD), Covance Inc. (NYSE: CVD), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on MD, CVD, PRXL and CRL can be downloaded upon signing up at:
Clinical Trial Management System (CTMS) Market 2014-2019
M2 - Tue Apr 22, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2ldhc/clinical_trial) has announced the addition of the "Clinical Trial Management System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019" report to their offering. Clinical trial management system (CTMS) is a software solution for proper management, storage and analysis of drugs associated clinical data. Globally, the CTMS market is witnessing significant growth due to increasing R&D investment in pharmaceutical, life science and clinical research industries.It empowers organizations and research centers to enhance productivity and effectiveness of clinical trials by advancing and managing clinical trials. Integration of CTMS with HIS provides more accurate and time saving documentation, and it is also one of the major driving factors for the growth of the CTMS market. Additionally, increasing prevalence of diseases is supporting clinical trials in different regions, and increased clinical research outsourcing is playing a major role in the growth of the CTMS market. Presence of various end users such as pharmaceuticals, clinical research organizations (CRO) and healthcare providers has increased the acceptance of CTMS. North America has the largest market share in the global CTMS market. Web based CTMS is the largest mode of delivery and pharmaceutical industry is the largest end user of CTMS. In terms of growth, Asia is the fastest growing region, cloud based CTMS is the fastest growing mode of delivery and CRO's are the fastest growing end users of CTMS. North American market for CTMS was estimated at USD 514.4 million in 2013 and is expected to reach USD 1,107.5 million in 2019, growing at a CAGR of 13.6% from 2013 to 2019. Software segment was estimated at USD 585 million in 2013 and is expected to reach USD 1,274.2 million in 2019, growing at a CAGR of 13.9% from 2013 to 2019. Key Topics Covered: - Preface - Executive Summary - Market Overview - Market Trends - Porters Five Force Analysis - Global Market Size and Forecast - Segment Analysis by Delivery Mode - Segment Analysis by End User - Segment Analysis by Type - Segment Analysis by Components - Regional Analysis - Competitive Landscape - Company Profiles - Bio-Optronics - BioClinica - DSG - eClinForce - Forte Research Systems - MedNet Solutions - Medidata - Merge Healthcare Inc. - Oracle Corporation - PAREXEL International Corporation For more information visit http://www.researchandmarkets.com/research/g2...ical_trial
PAREXEL Appoints Peter Steiger, Ph.D., As Vice President Of Medical Imaging In Its Technology Subsidiary
PR Newswire - Mon Apr 14, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the appointment of Peter Steiger, Ph.D., to the newly created position of Vice President and Chief Scientific Officer for Medical Imaging. Dr. Steiger, who has more than 25 years of experience in the application of specialized medical imaging techniques in support of biopharmaceutical product development, will oversee the worldwide medical imaging scientific strategy at PAREXEL Informatics. PAREXEL Informatics provides advanced technology solutions to facilitate the clinical development process.
Upcoming Financial Results, Recent Investments and Agreements, and Expanded Collaborations - Analyst Notes on PerkinElmer, PAREXEL, WuXi, Response Genetics, and Foundation Medicine
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Response Genetics, Inc. (NASDAQ: RGDX), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
PAREXEL International elects two SVPs of Clinical Research Services
M2 - Mon Apr 07, 9:33AM CDT
Biopharmaceutical company PAREXEL International (NasdaqGS RXL) revealed on Monday the addition of Roland Andersson PhD, and Thomas Senderovitz MD, as senior vice presidents of its Clinical Research Services (CRS) strategic business unit.
Uptrend Call Working As Parexel International Stock Rises 12.1% (PRXL)
Comtex SmarTrend(R) - Mon Apr 07, 9:21AM CDT
SmarTrend identified an Uptrend for Parexel International (NASDAQ RXL) on December 24th, 2013 at $44.68. In approximately 3 months, Parexel International has returned 12.08% as of today's recent price of $50.07.
PAREXEL Strengthens Executive Leadership With Appointments Of Roland Andersson, Ph.D. And Thomas Senderovitz, M.D. As Senior Vice Presidents Of Clinical Research Services
PR Newswire - Mon Apr 07, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced Dr. Roland Andersson, Ph.D., and Dr. Thomas Senderovitz, M.D., as Senior Vice Presidents in the Company's Clinical Research Services (CRS) strategic business unit. The executives will be centrally involved in developing and implementing PAREXEL's global corporate objectives.
PAREXEL Announces Date of Third Quarter Fiscal Year 2014 Earnings Release and Conference Call
GlobeNewswire - Tue Apr 01, 8:30AM CDT
PAREXEL International Corporation (Nasdaq RXL) will release financial results for the Third Quarter of Fiscal Year 2014 on Tuesday, April 29, 2014 after the close of the stock market. The announcement will be available on PAREXEL's website at www.PAREXEL.com and on the PRNewswire website at www.prnewswire.com.
Strategic Partnerships Perceived As Most Effective Biopharmaceutical Outsourcing Model In Meeting Key Sponsor Needs, PAREXEL Report Reveals
PR Newswire Europe - Mon Mar 31, 5:01AM CDT
-- More than half of biopharmaceutical companies surveyed use a Strategic Partnership model
4 Disruptive Stocks Biotechs Depend On
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 5:30PM CDT
It's easy for investors to fall into the trap of chasing markets higher and lower, especially when the media machine hypes booms and busts. However, investors that chase market pops and drops rarely come out ahead in the long haul. Instead,...
Healthcare Companies Make Presentations, Submissions, Investigation Extensions, and Expansions - Analyst Notes on CR Bard, Medivation, Align Technology, Covance, and PAREXEL
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CR Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and PAREXEL International Corporation (NASDAQ: PRXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Post Earnings Update: Parexel International Has Climbed 0.9% Higher in Past Week (PRXL)
Comtex SmarTrend(R) - Mon May 12, 11:22AM CDT
When Parexel International (NASDAQ
RXL) reported earnings 13 days ago on April 29th, 2014, analysts, on average, expected the company to report earnings of $0.54 on sales of $493.3 million. Parexel International actually reported earnings of $0.56 per share on sales of $577.9 million, beating EPS estimates by $0.02 and beating revenue estimates by $84.6 million. Shares of Parexel International have climbed from $45.48 to $45.91, representing a gain of 0.9% since the company reported earnings 13 days ago. PAREXEL Chairman And CEO Named 2014 Immigrant Entrepreneur of the Year in Life Sciences
PR Newswire - Fri May 09, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that its Chairman and CEO, Josef von Rickenbach, was named 2014 Immigrant Entrepreneur of the Year in Life Sciences by the Immigrant Learning Center of Malden, Mass. He received the award May 8, 2014, during the third annual Immigrant Entrepreneur Awards Dinner in Cambridge, Mass.
Healthcare Companies Report Studies, Financial Results, and Upcoming Conferences - Analyst Notes on Vertex, PerkinElmer, PAREXEL, ACADIA Pharmaceuticals and Arena Pharmaceuticals
PR Newswire - Thu May 08, 11:31AM CDT
Today, Analysts Review released its analysts' notes regarding Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2188-100free.
PAREXEL International to Present at Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Tue May 06, 9:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas, NV. James Winschel, Executive Vice President, will be making a presentation on PAREXEL and discussing business developments at 4:20 p.m. PDT on Tuesday, May 13, 2014.
PAREXEL Q3 Earnings & Revs Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 2:00PM CDT
For fiscal 2014, PAREXEL International Corporation (PRXL) increased its adjusted EPS guidance to a range of $2.11 to $2.15 from the prior range of $2.01 to $2.11.
Water-Logged And Getting Wetter Stock Of The Day: Parexel International (PRXL)
at The Street - Wed Apr 30, 9:08AM CDT
Trade-Ideas LLC identified Parexel International (PRXL) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
PAREXEL International Reports Third Quarter Fiscal Year 2014 Results
PR Newswire - Tue Apr 29, 3:06PM CDT
PAREXEL International Corporation (NASDAQ: PRXL) today reported financial results for the third quarter of Fiscal Year 2014, which ended on March 31, 2014.
Technical Coverage on Health Care Equities -- Research on MEDNAX, Covance, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Apr 22, 11:55AM CDT
On Monday, April 21, 2014, the NASDAQ Composite ended at 4,121.55, up 0.64%, the Dow Jones Industrial Average advanced 0.25% to 16,449.25, and the S&P 500 closed at 1,871.89, up 0.38%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 666.48, up 1.20%, while the same has declined 3.26% in the last one month. Investor-Edge has initiated coverage on the following equities: MEDNAX Inc. (NYSE: MD), Covance Inc. (NYSE: CVD), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on MD, CVD, PRXL and CRL can be downloaded upon signing up at:
Clinical Trial Management System (CTMS) Market 2014-2019
M2 - Tue Apr 22, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2ldhc/clinical_trial) has announced the addition of the "Clinical Trial Management System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019" report to their offering. Clinical trial management system (CTMS) is a software solution for proper management, storage and analysis of drugs associated clinical data. Globally, the CTMS market is witnessing significant growth due to increasing R&D investment in pharmaceutical, life science and clinical research industries.It empowers organizations and research centers to enhance productivity and effectiveness of clinical trials by advancing and managing clinical trials. Integration of CTMS with HIS provides more accurate and time saving documentation, and it is also one of the major driving factors for the growth of the CTMS market. Additionally, increasing prevalence of diseases is supporting clinical trials in different regions, and increased clinical research outsourcing is playing a major role in the growth of the CTMS market. Presence of various end users such as pharmaceuticals, clinical research organizations (CRO) and healthcare providers has increased the acceptance of CTMS. North America has the largest market share in the global CTMS market. Web based CTMS is the largest mode of delivery and pharmaceutical industry is the largest end user of CTMS. In terms of growth, Asia is the fastest growing region, cloud based CTMS is the fastest growing mode of delivery and CRO's are the fastest growing end users of CTMS. North American market for CTMS was estimated at USD 514.4 million in 2013 and is expected to reach USD 1,107.5 million in 2019, growing at a CAGR of 13.6% from 2013 to 2019. Software segment was estimated at USD 585 million in 2013 and is expected to reach USD 1,274.2 million in 2019, growing at a CAGR of 13.9% from 2013 to 2019. Key Topics Covered: - Preface - Executive Summary - Market Overview - Market Trends - Porters Five Force Analysis - Global Market Size and Forecast - Segment Analysis by Delivery Mode - Segment Analysis by End User - Segment Analysis by Type - Segment Analysis by Components - Regional Analysis - Competitive Landscape - Company Profiles - Bio-Optronics - BioClinica - DSG - eClinForce - Forte Research Systems - MedNet Solutions - Medidata - Merge Healthcare Inc. - Oracle Corporation - PAREXEL International Corporation For more information visit http://www.researchandmarkets.com/research/g2...ical_trial
PAREXEL Appoints Peter Steiger, Ph.D., As Vice President Of Medical Imaging In Its Technology Subsidiary
PR Newswire - Mon Apr 14, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the appointment of Peter Steiger, Ph.D., to the newly created position of Vice President and Chief Scientific Officer for Medical Imaging. Dr. Steiger, who has more than 25 years of experience in the application of specialized medical imaging techniques in support of biopharmaceutical product development, will oversee the worldwide medical imaging scientific strategy at PAREXEL Informatics. PAREXEL Informatics provides advanced technology solutions to facilitate the clinical development process.
Upcoming Financial Results, Recent Investments and Agreements, and Expanded Collaborations - Analyst Notes on PerkinElmer, PAREXEL, WuXi, Response Genetics, and Foundation Medicine
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Response Genetics, Inc. (NASDAQ: RGDX), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
PAREXEL International elects two SVPs of Clinical Research Services
M2 - Mon Apr 07, 9:33AM CDT
Biopharmaceutical company PAREXEL International (NasdaqGS
RXL) revealed on Monday the addition of Roland Andersson PhD, and Thomas Senderovitz MD, as senior vice presidents of its Clinical Research Services (CRS) strategic business unit. Uptrend Call Working As Parexel International Stock Rises 12.1% (PRXL)
Comtex SmarTrend(R) - Mon Apr 07, 9:21AM CDT
SmarTrend identified an Uptrend for Parexel International (NASDAQ
RXL) on December 24th, 2013 at $44.68. In approximately 3 months, Parexel International has returned 12.08% as of today's recent price of $50.07. PAREXEL Strengthens Executive Leadership With Appointments Of Roland Andersson, Ph.D. And Thomas Senderovitz, M.D. As Senior Vice Presidents Of Clinical Research Services
PR Newswire - Mon Apr 07, 5:00AM CDT
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced Dr. Roland Andersson, Ph.D., and Dr. Thomas Senderovitz, M.D., as Senior Vice Presidents in the Company's Clinical Research Services (CRS) strategic business unit. The executives will be centrally involved in developing and implementing PAREXEL's global corporate objectives.
PAREXEL Announces Date of Third Quarter Fiscal Year 2014 Earnings Release and Conference Call
GlobeNewswire - Tue Apr 01, 8:30AM CDT
PAREXEL International Corporation (Nasdaq
RXL) will release financial results for the Third Quarter of Fiscal Year 2014 on Tuesday, April 29, 2014 after the close of the stock market. The announcement will be available on PAREXEL's website at www.PAREXEL.com and on the PRNewswire website at www.prnewswire.com. Strategic Partnerships Perceived As Most Effective Biopharmaceutical Outsourcing Model In Meeting Key Sponsor Needs, PAREXEL Report Reveals
PR Newswire Europe - Mon Mar 31, 5:01AM CDT
-- More than half of biopharmaceutical companies surveyed use a Strategic Partnership model
4 Disruptive Stocks Biotechs Depend On
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 5:30PM CDT
It's easy for investors to fall into the trap of chasing markets higher and lower, especially when the media machine hypes booms and busts. However, investors that chase market pops and drops rarely come out ahead in the long haul. Instead,...
Healthcare Companies Make Presentations, Submissions, Investigation Extensions, and Expansions - Analyst Notes on CR Bard, Medivation, Align Technology, Covance, and PAREXEL
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CR Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and PAREXEL International Corporation (NASDAQ: PRXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
